IBD NEVER QUITS.
Neither will we.
Inflammatory bowel diseases (IBD) affect 10 million people worldwide.1 In spite of significant scientific progress in the understanding of chronic inflammatory diseases, many patients continue to face challenges controlling their disease.2 At Gilead, we are committed to working with you to help address these challenges and, ultimately, to improve the lives of patients living with IBD.